Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nivolumab, Nivolumab Injection [Opdivo], nivolumab, Neoadjuvant nivolumab, Nivolumab -, nivolumab 480mg
Nivolumab and rHuPH20 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Arm B | ACTIVE_COMPARATOR | - |
| Arm C | EXPERIMENTAL | - |
| Arm D | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Nivolumab and rHuPH20 | BIOLOGICAL | Specified dose on specified days |
| Nivolumab | BIOLOGICAL | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histological confirmation of renal cell carcinoma (RCC) with a clear cell component, including participants who may also have sarcomatoid features * Advanced...
BMS-936558, also known as nivolumab, is an investigational oncology drug being studied for brain cancer, advanced renal cell carcinoma, chronic myeloid leukemia, lymphoma, metastatic non-squamous non-small cell lung cancer, and neoplasms by site. It is developed by Bristol-Myers Squibb Company (BMY) and is currently in Phase 1 clinical development.
BMS-936558 targets PDCD1, also known as programmed cell death protein 1, and acts as an inhibitor of this target. By inhibiting PDCD1, the drug is designed to modulate immune responses in the treatment of various cancers, including non-small cell lung cancer and other solid tumors.
BMS-936558 is developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY. The drug is also known as nivolumab and is being investigated for multiple oncology indications.
BMS-936558 is in Phase 1 clinical development. It has received FDA designations of Breakthrough Therapy and Priority Review. The drug is investigational and not yet approved, with 14 total clinical trials, 5 active and 9 completed, involving 6,828 participants.
BMS-936558 is being studied in several clinical trials, including NCT01454102 (CheckMate 012) in non-small cell lung cancer, NCT02574078 in advanced NSCLC, NCT04123379 as neoadjuvant therapy for NSCLC or hepatocellular carcinoma, and NCT06946797 evaluating subcutaneous nivolumab with ipilimumab and chemotherapy in NSCLC.
Yes, BMS-936558 is the same as nivolumab, which is also known as Nivolumab Injection [Opdivo]. Other names include Neoadjuvant nivolumab, Nivolumab 10 MG/ML, and Nivolumab 240 mg, among others. It is being developed by Bristol-Myers Squibb Company.